Zobrazeno 1 - 10
of 235
pro vyhledávání: '"Virote Sriuranpong"'
Autor:
Piyada Sitthideatphaiboon, Chonnipa Nantavithya, Poonchavist Chantranuwat, Chanida Vinayanuwattikun, Virote Sriuranpong
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-11 (2024)
Abstract Preclinical studies suggest that loss of LKB1 expression renders cancer cells less responsive to radiation partly through NRF2-mediated upregulation of antioxidant enzymes protecting against radiation-induced DNA damage. Here we investigated
Externí odkaz:
https://doaj.org/article/d5a45dd16ddd41eeb5d1654676b4d9f2
Publikováno v:
Cancer Biology & Medicine, Vol 21, Iss 1, Pp 10-15 (2024)
Externí odkaz:
https://doaj.org/article/a1693d735a8a4f85ba10480fb07bd56e
Autor:
Jayesh Desai, Stephane Dalle, Jermaine Coward, Daniel Brungs, Andrew Mant, Margaret McGrath, Andrea Tazbirkova, Piotr Koralewski, Iwona Lugowska, Arunee Dechaphunkul, Virote Sriuranpong, James Oliviero, Philip Clingan, Rahul Ladwa, Eva Muñoz-Couselo, Henri Montaudié, Miguel-Ángel Berciano-Guerrero, Dean Laurence Harris, Susan Arnold, Samuel Fourie, Andriy Kurochkin, Daniel R Malan, Vinay Sharma, Hong Shue, Chaiyut Charoentum, Oleksandr Dudnichenko
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss 10 (2023)
Background Programmed cell death receptor-1 (PD-1)-blocking antibodies are approved to treat metastatic or locally advanced cutaneous squamous cell carcinoma (CSCC) cases ineligible for curative surgery or radiation. Notwithstanding, some patients ex
Externí odkaz:
https://doaj.org/article/ba79bd85b8124e27b03c0ee657e71ed1
Autor:
Piyada Sitthideatphaiboon, Chinachote Teerapakpinyo, Krittiya Korphaisarn, Nophol Leelayuwatanakul, Nopporn Pornpatrananrak, Naravat Poungvarin, Poonchavist Chantranuwat, Shanop Shuangshoti, Chatchawit Aporntewan, Wariya Chintanapakdee, Virote Sriuranpong, Chanida Vinayanuwattikun
Publikováno v:
Scientific Reports, Vol 12, Iss 1, Pp 1-13 (2022)
Abstract Despite the development of predictive biomarkers to shape treatment paradigms and outcomes, de novo EGFR TKI resistance advanced non-small cell lung cancer (NSCLC) remains an issue of concern. We explored clinical factors in 332 advanced NSC
Externí odkaz:
https://doaj.org/article/eb87e0916f2c489da4b90d111e11c6aa
Autor:
Nuttapong Ngamphaiboon, Suthinee Ithimakin, Teerada Siripoon, Nattaya Sintawichai, Virote Sriuranpong
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-12 (2021)
Abstract Background Most immune-related adverse event (irAE) patterns and treatment guidelines are based on western clinical data. We evaluated the incidence and patterns of irAEs in patients treated with immune-checkpoint inhibitors (ICI) in Thailan
Externí odkaz:
https://doaj.org/article/fb17b7216d0644f4989caa98b9fbf9db
Autor:
Nussara Pakvisal, Panot Sainamthip, Nattaya Teeyapun, Sutima Luangdilok, Nassamon Wanlapakorn, Ritthideach Yorsaeng, Yong Poovorawan, Piyapoom Pakvisal, Thiti Susiriwatananont, Nicha Zungsontiporn, Virote Sriuranpong, Suebpong Tanasanvimon, Passakorn Wanchaijiraboon
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 18, Iss 6 (2022)
The study aimed to evaluate vaccine-related adverse events (VRAEs) following ChAdOx1-nCoV-19 vaccine in solid cancer patients receiving treatment compared to healthy controls. 399 cancer patients and 90 healthy volunteers were enrolled. In the overal
Externí odkaz:
https://doaj.org/article/1a3266a837cc424ba86d3a059ad64f26
Autor:
Nattaya Teeyapun, Sutima Luangdilok, Nussara Pakvisal, Panot Sainamthip, Siyamol Mingmalairak, Nattaya Poovorawan, Piyada Sitthideatphaiboon, Napa Parinyanitikul, Virote Sriuranpong, Teerayuth Namkanisorn, Pratchaya Inthasuwan, Pattama Angspatt, Ploytuangporn Wongchanapat, Akradach Bamrungnam, Nutchanok Leeleakpai, Sutheera Uttha, Supaporn Jaichum, Peerawich Kongkaew, Chayanin Suksanong, Rattiya Veranitinun, Ampai Prasomphol, Chada Sartsuk, Cheeraporn Patcharajutanon, Supreeya Preaprang, Hathairat Choengsamor, Rungthong Phongwan, Charoenpit Preeyasaksa, Ekkamol Phaibulvatanapong, Nungruthai Suntronwong, Ritthideach Yorsaeng, Preeyaporn Vichaiwattana, Nasamon Wanlapakorn, Stephen J. Kerr, Yong Poovorawan, Passakorn Wanchaijiraboon, Suebpong Tanasanvimon
Publikováno v:
EClinicalMedicine, Vol 52, Iss , Pp 101608- (2022)
Summary: Background: Limited data exists regarding the efficacy of ChAdOx1-nCoV-19 vaccine against Severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2) in solid cancer patients. We aimed to assess the immunogenicity of the ChAdOx1-nCoV-19
Externí odkaz:
https://doaj.org/article/6ed0be156f70417b98b3d3752eb55f69
Autor:
Hope S. Rugo, Eduardo J. Pennella, Unmesh Gopalakrishnan, Miguel Hernandez-Bronchud, Jay Herson, Hans Friedrich Koch, Subramanian Loganathan, Sarika Deodhar, Ashwani Marwah, Alexey Manikhas, Igor Bondarenko, Joseph D. Parra, Maria Luisa T. Abesamis-Tiambeng, Charuwan Akewanlop, Ihor Vynnychenko, Virote Sriuranpong, Sirshendu Roy, Eduardo Patricio Yanez Ruiz, Abhijit Barve, Cornelius F. Waller
Publikováno v:
Breast, Vol 58, Iss , Pp 18-26 (2021)
Background: Trastuzumab-dkst is a biosimilar of trastuzumab. The phase 3 HERITAGE trial demonstrated equivalent overall response rate (ORR) with trastuzumab-dkst or originator trastuzumab at 24 weeks in patients with HER2-positive metastatic breast c
Externí odkaz:
https://doaj.org/article/398ce9856ea34116bdedd35208f23846
Autor:
Passakorn Wanchaijiraboon, Panot Sainamthip, Nattaya Teeyapun, Sutima Luangdilok, Yong Poovorawan, Nasamon Wanlapakorn, Suebpong Tanasanvimon, Virote Sriuranpong, Thiti Susiriwatananont, Nicha Zungsontiporn, Nussara Pakvisal
Publikováno v:
Vaccines, Vol 11, Iss 2, p 356 (2023)
Safety data following the COVID-19 booster mRNA vaccine in solid cancer patients are scarce. We prospectively evaluated adverse events after a booster dose of the BNT162b2 vaccine as compared to the mRNA-1273 vaccine in solid malignancy patients who
Externí odkaz:
https://doaj.org/article/7b609b8e83ae4e269804e0645aba8b73
Autor:
Chawalit Chayangsu, Jiraporn Khorana, Chaiyut Charoentum, Virote Sriuranpong, Jayanton Patumanond, Apichat Tantraworasin
Publikováno v:
Healthcare, Vol 11, Iss 3, p 293 (2023)
The outcomes of advanced non-small cell lung cancer (NSCLC) patients have been significantly improved with novel therapies, such as tyrosine kinase inhibitors and immune checkpoint inhibitors. However, in resource-limited countries, platinum-doublet
Externí odkaz:
https://doaj.org/article/985b1c4738c741c69d134650892395cf